Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0SY6T
|
||||
| Former ID |
DNC014629
|
||||
| Drug Name |
1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H22N2O
|
||||
| Canonical SMILES |
CC1=CC(=CC=C1)NC(=O)NCC=C(C2=CC=CC=C2)C3=CC=CC=C3
|
||||
| InChI |
1S/C23H22N2O/c1-18-9-8-14-21(17-18)25-23(26)24-16-15-22(19-10-4-2-5-11-19)20-12-6-3-7-13-20/h2-15,17H,16H2,1H3,(H2,24,25,26)
|
||||
| InChIKey |
AQCRRYHNTDGOLK-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cholecystokinin receptor type A | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Insulin secretion | |||||
| Pancreatic secretion | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.